While the world awaits a vaccine, drugmakers—and the US
government—are throwing resources behind a potential stop-gap solution:
custom antibodies designed to fight COVID-19.
Grown in bioreactor vats, these monoclonal antibodies are copies of
naturally occurring proteins.
Already used against cancer and other disorders, the method has been
endorsed by big-name scientists including Anthony Fauci, who says they
are “almost a sure bet” against COVID-19.
But unlike a vaccine, the immunity provided would wane.
Drugmakers are racing to find the ideal combination of antibodies to take
on COVID-19, and rival drugmakers have been cleared to join their
manufacturing forces if any one drug gets the green light.
Regeneron says antibody cocktail prevents and treats COVID-19 in animals